On This Day in Health: March 20, 2018
On March 20, 2018, the United States Food and Drug Administration expanded the approval of brentuximab vedotin, marketed as Adcetris, to include an initial treatment combination for advanced classical Hodgkin lymphoma. The authorization covered adults with previously untreated stage III or IV disease, using the medicine with three chemotherapy drugs. Adcetris already had approved uses, so this anniversary marks a new place in treatment rather than the drug's first arrival. It brought a targeted component into an established area of cancer care after a large comparative clinical trial examined the combination's benefits and risks.
Brentuximab vedotin is an antibody-drug conjugate. Its antibody recognizes CD30, a protein expressed by the characteristic cells of classical Hodgkin lymphoma, and carries a cell-killing agent linked to it. The treatment combines recognition of a cellular target with delivery of a potent drug. That design differs from an antibody that mainly releases a brake on the immune system. In the newly authorized regimen, Adcetris was paired with doxorubicin, vinblastine, and dacarbazine, collectively called AVD. The comparison regimen included those medicines plus bleomycin, which was omitted from the Adcetris combination.
The ECHELON-1 study enrolled 1,334 patients with previously untreated advanced classical Hodgkin lymphoma. Its principal outcome was modified progression-free survival, a measure incorporating progression, death, and additional anticancer treatment for patients who had not achieved a complete response. The trial found a statistically significant improvement on that measure with Adcetris plus AVD compared with ABVD. The reported relative reduction in the risk of those combined events was twenty-three percent. That result was not a twenty-three percent reduction in mortality alone. At the time of the initial analysis, the overall survival comparison had not shown a statistically significant difference.
The new regimen also required close attention to adverse effects, including nerve problems and low white blood cell counts. Its regulatory assessment considered supportive measures alongside the main cancer treatment. The historical importance of March 20 lies in the evidence-based expansion of a medicine's role: a drug already used in other settings could become part of initial care after a different clinical question had been tested. It also illustrates why the wording of a trial outcome matters. Understanding what was measured prevents a promising result from becoming an exaggerated claim. The anniversary records a meaningful change in available treatment, grounded in a defined patient population, an active comparison, and continued evaluation of both benefit and harm across the full course of care.
The March decision expanded an existing medicine's indication. It authorized a combination for previously untreated advanced disease.
Adcetris links a CD30-targeting antibody to a cell-killing agent. It belongs to the antibody-drug conjugate class.
The authorized combination used AVD chemotherapy. Bleomycin was omitted from that regimen.
ECHELON-1 enrolled 1,334 patients. Its comparator was an established active chemotherapy combination.
The main outcome combined several kinds of events. Its relative reduction was not a mortality reduction alone.
Nerve problems and low white blood cell counts remained important risks. Supportive care formed part of the treatment framework.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.